Literature DB >> 1394346

Confusion about the tissue distribution of lymphokine-activated killer (LAK) cells.

A A Maghazachi.   

Abstract

Mesh：

Year:  1992        PMID： 1394346     DOI： 10.1007/bf01789023

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  17 in total

1.  Changes in homing receptor expression on murine lymphokine-activated killer cells during IL-2 exposure.

Authors:  P D Steen; J R McGregor; C M Lehman; W E Samlowski
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

2.  Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.

Authors:  T Hercend; F Farace; D Baume; F Charpentier; J P Droz; F Triebel; B Escudier
Journal:  J Biol Response Mod       Date:  1990-12

3.  Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.

Authors:  M Rodolfo; C Salvi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.

Authors:  M Rodolfo; C Salvi; C Bassi; M Sensi; G Parmiani
Journal:  Ann Ist Super Sanita       Date:  1990       Impact factor: 1.663

5.  In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats.

Authors:  R E Felgar; J C Hiserodt
Journal:  Cell Immunol       Date:  1990-09       Impact factor: 4.868

6.  Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.

Authors:  M Hosokawa; Y Sawamura; T Morikage; F Okada; Z Y Xu; K Morikawa; K Itoh; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Imaging pattern of previously in vitro sensitized and interleukin-2 expanded autologous lymphocytes in human cancer.

Authors:  B Mukherji; O Arnbjarnarson; L A Spitznagle; R I Kalish; J Hoffman; M T Ergin; R P Spencer
Journal:  Int J Rad Appl Instrum B       Date:  1988

8.  In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells.

Authors:  A A Maghazachi; R B Herberman; N L Vujanovic; J C Hiserodt
Journal:  Cell Immunol       Date:  1988-08       Impact factor: 4.868

9.  In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells.

Authors:  H Futami; A M Pilaro; M E Gruys; T C Back; H A Young; R H Wiltrout
Journal:  Biotherapy       Date:  1991

10.  Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.

Authors:  B Fisher; B S Packard; E J Read; J A Carrasquillo; C S Carter; S L Topalian; J C Yang; P Yolles; S M Larson; S A Rosenberg
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.